Business Wire

AppOnboard App Store Demos are Unlocking Explosive Growth of Apps and Games in Emerging Markets via Google Play Instant

Jaa

Today AppOnboard, a mobile app demo technology and analytics platform for developers, has announced that AppOnboard’s App Store Demos have experienced wide global adoption since launching in late August, especially in emerging markets. App Store Demos allow users to demo apps and games directly on the Google Play Store without a download, via Google Play Instant.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181018005368/en/

AppOnboard's App Store Demo for FoxNext Games' MARVEL Strike Force (Photo: Business Wire)

AppOnboard's App Store Demo for FoxNext Games' MARVEL Strike Force (Photo: Business Wire)

"AppOnboard and its technology has been one of the driving factors for this growth,” said Google’s Ben Frenkel. “Many developers have leveraged App Store Demos to enable their Google Play Instant apps quickly and without needing to dedicate their own engineering resources."

Today, Google holds its annual Google Playtime event in Berlin and San Francisco, where top developers from around the world gather to discuss the latest features and best practices for Android and Google Play.

“The appetite for the ‘Try Now’ button on Google Play rivals anything I have seen in mobile since the launch of mobile app stores,” said Jonathan Zweig, CEO of AppOnboard.

India and Brazil have been particularly big consumers of App Store Demos to-date. With many international countries lacking comprehensive 3G/4G coverage and WiFi options, Google’s “Try Now” button is becoming the default user behavior for experiencing apps in these countries. Previously, apps and games would have to be downloaded in their entirety before they could be tried or demoed.

“App Store Demos, and the Google Play Instant product, are perfect solutions for users in emerging markets,” said Bryan Buskas, COO AppOnboard. “These Instant Apps unlock previously inaccessible content and put them at the fingertips of every consumer.”

Since launching with its initial set of partners in August, including Jam City, Scopely, Huuuge Games, and Simple Habit, AppOnboard has since helped more global developers activate their “Try Now” buttons quickly and effectively. Superheart Studios recently leveraged an App Store Demo to gauge Android interest for its 3D aquarium game, Ocean Reef Life, and has driven 10,000 daily pre-registrations. Two other worldwide developers, FoxNext Games and Game Insight, were able to showcase their 3D games, MARVEL Strike Force and Guns of Boom, as Google Play Instant apps through the use of AppOnboard technology.

“Getting new users to convert from curious to installed has always been the industry's biggest challenge,” said Anatoly Ropotov, CEO at Game Insight. “By partnering with AppOnboard to build our Google Play Instant app, we were able to give potential players a taste of what Guns of Boom has to offer through an instant demo that faithfully reflects the game."

MARVEL Strike Force, a hit Mobile Squad Based Superhero game from FoxNext, partnered with AppOnboard to enable its “Try Now” button at the end of September. The game is currently the #2 Top Grossing app on the Google Play Store and has amassed 5 million downloads to-date.

“The Google Play Instant program is great because it prequalifies players and lets them try a game to see if it is up their alley,” said Sebastian Kriese, Vice President, Platform Relations at FoxNext Games. “We at FoxNext Games were impressed by the 3D quality our App Store Demo was able to achieve, and we launched our ‘Try Now’ button much faster thanks to the help of AppOnboard.”

App Store Demos leverage AppOnboard’s playable demo engine, optimized creative, and user behavior analytics and help developers launch their Google Play Instant apps quickly and effectively. In addition to giving users the ability to demo the app or game on the storefront, developers are also driving higher quality users by launching App Store Demos. Those users who engage with an App Store Demo prior to installing have shown higher retention (+32% D1, +29% D7) and have been more likely to become paying users (+44% D1, +37% D7) when compared to users who install right away.

For more information on AppOnboard or to claim your 30-day free trial of App Store Demos, please visit: play.apponboard.com.

About AppOnboard:

AppOnboard is a mobile app demo and analytics platform that powers Full-Fidelity Demos, which allow users to instantly experience an app or game without downloading it. AppOnboard enables app and game testing as well as product insights and optimization for developers. Founded in 2016 and headquartered in Los Angeles with offices in San Francisco and Seattle, AppOnboard is venture-backed by Korea Investment Partners (KIP), Mirae Asset Management, Mantaray, MTG, Ophir Capital Group, Runa Capital, Troy Capital Partners, 500 Startups and London Venture Partners.

Contact information

AppOnboard
Bryan Buskas, 1-424-293-2501
contact@apponboard.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Vertex Announces European Commission Approval for ORKAMBI® (lumacaftor/ivacaftor) for Treatment of Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease21.1.2019 12:00Tiedote

Vertex Pharmaceuticals (Europe) Limited today announced that the European Commission has granted approval of the label extension for ORKAMBI® (lumacaftor/ivacaftor) for the treatment of children with cystic fibrosis (CF) aged 2 to 5 years old who have two copies of the F508del mutation, the most common form of the disease. “Today’s approval by the European Commission brings us one step closer to our goal of bringing treatment to all people living with CF,” said Reshma Kewalramani, MD, Executive Vice President, Global Medicines Development and Medical Affairs and Chief Medical Officer at Vertex. ‘‘By treating the underlying cause of disease early, we can potentially modify its course and offer patients the chance of improved outcomes.’’ The label update is based on data from a Phase 3 open-label safety study in 60 patients that showed treatment with lumacaftor/ivacaftor was generally well tolerated for 24 weeks, with a safety profile in these pediatric patients generally consistent with

Anticipation Builds as MWC19 Barcelona Approaches21.1.2019 12:00Tiedote

The GSMA today announced final updates for MWC19 Barcelona (formerly Mobile World Congress), including additional keynote speakers, participating companies, programmes and events. Taking place 25-28 February 2019, with events being staged at Fira Gran Via, Fira Montjuïc and La Farga L’Hospitalet, MWC19 Barcelona is set to attract more than 107,000 professionals from over 200 countries and territories. “With the anticipated arrival of 5G, this year’s event is set to be one of the most exciting as the industry convenes to showcase Intelligent Connectivity across new technologies on the brink of reaching millions of people across the world,” said John Hoffman, CEO, GSMA Ltd. “Over the four days of MWC19, attendees will have the opportunity to hear from leaders who are driving innovation and we look forward once again to welcoming the mobile world to Barcelona.” Global Leaders to Keynote The GSMA announced the addition of several new keynote speakers for MWC19 including executives from lea

B2C2 Launches Streaming OTC Pricing with Point-and-Click Execution21.1.2019 12:00Tiedote

B2C2, one of the largest cryptocurrency liquidity providers and the leader in electronic OTC trading, today announced the launch of streaming pricing with point-and-click execution on its OTC platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190121005063/en/ Max Boonen, Founder and CEO of B2C2 (Photo: Business Wire) For the first time, B2C2’s clients will be able to view and execute trades on a real-time two-way market, via the firm’s secure web interface. The new functionality allows market participants to easily monitor live pricing in user-defined quantities and execute with the click of a button, as they would on traditional FX trading platforms. The launch rounds out a number of milestones for B2C2 in 2018, including surpassing 2017 peak volumes; rolling out a completely redesigned front-end; forming integration partnerships with the major liquidity hubs; and launching a research offering. Founded in 2015, B2C2 i

Alnylam Pharmaceuticals and Medison Pharma Partner to Commercialize RNAi Therapeutics in Israel21.1.2019 11:00Tiedote

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Medison Pharma, Israel’s leading commercial partner for innovative pharmaceuticals, announced today an exclusive agreement to commercialize ONPATTRO®, the first-ever commercialized RNAi therapeutic, as well as other investigational therapeutics under development in the Alnylam RNAi portfolio. “Our partnership with Medison marks an important step in our global commercial expansion and signals our intent to ensure that patients suffering from serious rare diseases have access to our medicines, regardless of location,” said Theresa Heggie, SVP and Head of Europe, Middle East and Africa, and Canada, Alnylam Pharmaceuticals. “Medison has a strong organization with a proven track record of commercializing orphan products successfully, together with an infrastructure uniquely suited to supporting patients suffering from rare diseases in Israel and providing access to our potentially transformational thera

Gore Introduces GORE® TAG® Conformable Thoracic Stent Graft with Reduced Profiles in Europe21.1.2019 11:00Tiedote

W. L. Gore & Associates, Inc. (Gore) today introduced reduced profiles for the most commonly used diameters of the GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System. The reduced profile allows physicians to perform TEVAR in patients with smaller vessels where access is challenging and aortic anatomy is tortuous, expanding the availability of Gore’s thoracic stent graft to a greater population of patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190121005042/en/ GORE(R) TAG(R) Conformable Thoracic Stent Graft with ACTIVE CONTROL System (Photo: Business Wire) The GORE® TAG® Conformable Thoracic Stent Graft was modified to reduce the delivery profile of the 31, 37, and 40 mm device diameters by 2 Fr for all lengths. The reduction in profile, through the use of a smaller diameter primary sleeve, is the only change to the device. The stent graft leverages the same predictable outcomes of the time-teste

HCL 2030 Ecosystem Platform to Explore Societal Implications of Emerging Technology at the World Economic Forum21.1.2019 10:26Tiedote

HCL Technologies (HCL), a leading global technology company and the World Economic Forum’s Strategic Partner, today announced its largest presence to date at the side-lines of World Economic Forum’s Annual Meeting in Davos scheduled from 21st January 2019 to 25th January 2019. The company will host a three-day event in a special Pavilion that will feature a technology showcase, thought-leadership programs, as well as a number of high-level networking and social events throughout the tenure of the conference. The overarching theme of the HCL and Fast Company programs will explore how humanity’s relationship with technology will evolve through the next decade of rapid innovation. HCL has partnered with Fast Company to develop a thought-leadership track that includes three panel discussion breakfasts. As part of the theme of Human-Machine Harmony, HCL is launching the HCL 2030 Platform, together with its ecosystem of partners and stakeholders, that will conduct in-depth explorations and d

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme